vs
Harmony Biosciences Holdings, Inc.（HRMY）与ROGERS CORP（ROG）财务数据对比。点击上方公司名可切换其他公司
Harmony Biosciences Holdings, Inc.的季度营收约是ROGERS CORP的1.2倍（$243.8M vs $200.5M），Harmony Biosciences Holdings, Inc.净利率更高（9.2% vs 2.2%，领先7.0%），Harmony Biosciences Holdings, Inc.同比增速更快（21.1% vs 5.2%），Harmony Biosciences Holdings, Inc.自由现金流更多（$126.0M vs $1.1M），过去两年Harmony Biosciences Holdings, Inc.的营收复合增速更高（25.6% vs -3.3%）
哈莫尼生物科学控股公司是一家处于商业化阶段的生物制药企业，专注于罕见神经及中枢神经系统疾病创新疗法的研发与商业化，核心产品针对发作性睡病等睡眠相关中枢神经系统病症，主要市场为美国。
罗杰斯公司是一家专注于特种工程材料研发生产的企业，总部位于美国亚利桑那州钱德勒市，其产品广泛应用于先进电子、移动通信、清洁能源、航空航天等多个高科技领域，为全球客户提供高性能材料解决方案。
HRMY vs ROG — 直观对比
营收规模更大
HRMY
是对方的1.2倍
$200.5M
营收增速更快
HRMY
高出15.9%
5.2%
净利率更高
HRMY
高出7.0%
2.2%
自由现金流更多
HRMY
多$124.9M
$1.1M
两年增速更快
HRMY
近两年复合增速
-3.3%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $243.8M | $200.5M |
| 净利润 | $22.5M | $4.5M |
| 毛利率 | 71.9% | 32.2% |
| 营业利润率 | 15.8% | — |
| 净利率 | 9.2% | 2.2% |
| 营收同比 | 21.1% | 5.2% |
| 净利润同比 | -54.6% | 421.4% |
| 每股收益（稀释后） | $0.38 | $0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HRMYROG
| Q1 26 | — | $200.5M | ||
| Q4 25 | $243.8M | $201.5M | ||
| Q3 25 | $239.5M | $216.0M | ||
| Q2 25 | $200.5M | $202.8M | ||
| Q1 25 | $184.7M | $190.5M | ||
| Q4 24 | $201.3M | $192.2M | ||
| Q3 24 | $186.0M | $210.3M | ||
| Q2 24 | $172.8M | $214.2M |
净利润HRMYROG
| Q1 26 | — | $4.5M | ||
| Q4 25 | $22.5M | $4.6M | ||
| Q3 25 | $50.9M | $8.6M | ||
| Q2 25 | $39.8M | $-73.6M | ||
| Q1 25 | $45.6M | $-1.4M | ||
| Q4 24 | $49.5M | $-500.0K | ||
| Q3 24 | $46.1M | $10.7M | ||
| Q2 24 | $11.6M | $8.1M |
毛利率HRMYROG
| Q1 26 | — | 32.2% | ||
| Q4 25 | 71.9% | 31.5% | ||
| Q3 25 | 75.1% | 33.5% | ||
| Q2 25 | 81.0% | 31.6% | ||
| Q1 25 | 82.7% | 29.9% | ||
| Q4 24 | 73.0% | 32.1% | ||
| Q3 24 | 77.0% | 35.2% | ||
| Q2 24 | 81.4% | 34.1% |
营业利润率HRMYROG
| Q1 26 | — | — | ||
| Q4 25 | 15.8% | 3.5% | ||
| Q3 25 | 27.3% | 7.3% | ||
| Q2 25 | 24.0% | -33.3% | ||
| Q1 25 | 30.4% | -0.2% | ||
| Q4 24 | 27.7% | -6.6% | ||
| Q3 24 | 33.2% | 6.9% | ||
| Q2 24 | 12.4% | 5.3% |
净利率HRMYROG
| Q1 26 | — | 2.2% | ||
| Q4 25 | 9.2% | 2.3% | ||
| Q3 25 | 21.2% | 4.0% | ||
| Q2 25 | 19.8% | -36.3% | ||
| Q1 25 | 24.7% | -0.7% | ||
| Q4 24 | 24.6% | -0.3% | ||
| Q3 24 | 24.8% | 5.1% | ||
| Q2 24 | 6.7% | 3.8% |
每股收益（稀释后）HRMYROG
| Q1 26 | — | $0.25 | ||
| Q4 25 | $0.38 | $0.20 | ||
| Q3 25 | $0.87 | $0.48 | ||
| Q2 25 | $0.68 | $-4.00 | ||
| Q1 25 | $0.78 | $-0.08 | ||
| Q4 24 | $0.85 | $-0.04 | ||
| Q3 24 | $0.79 | $0.58 | ||
| Q2 24 | $0.20 | $0.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $775.3M | $195.8M |
| 总债务越低越好 | $163.7M | — |
| 股东权益账面价值 | $870.2M | $1.2B |
| 总资产 | $1.3B | $1.4B |
| 负债/权益比越低杠杆越低 | 0.19× | — |
8季度趋势，按日历期对齐
现金及短期投资HRMYROG
| Q1 26 | — | $195.8M | ||
| Q4 25 | $775.3M | $197.0M | ||
| Q3 25 | $672.6M | $167.8M | ||
| Q2 25 | $565.3M | $157.2M | ||
| Q1 25 | $507.0M | $175.6M | ||
| Q4 24 | $467.2M | $159.8M | ||
| Q3 24 | $410.5M | $146.4M | ||
| Q2 24 | $346.9M | $119.9M |
总债务HRMYROG
| Q1 26 | — | — | ||
| Q4 25 | $163.7M | — | ||
| Q3 25 | $168.5M | — | ||
| Q2 25 | $172.1M | — | ||
| Q1 25 | $175.7M | — | ||
| Q4 24 | $179.3M | — | ||
| Q3 24 | $182.8M | — | ||
| Q2 24 | $186.4M | — |
股东权益HRMYROG
| Q1 26 | — | $1.2B | ||
| Q4 25 | $870.2M | $1.2B | ||
| Q3 25 | $835.1M | $1.2B | ||
| Q2 25 | $773.1M | $1.2B | ||
| Q1 25 | $720.5M | $1.3B | ||
| Q4 24 | $659.2M | $1.3B | ||
| Q3 24 | $596.8M | $1.3B | ||
| Q2 24 | $538.6M | $1.3B |
总资产HRMYROG
| Q1 26 | — | $1.4B | ||
| Q4 25 | $1.3B | $1.4B | ||
| Q3 25 | $1.2B | $1.4B | ||
| Q2 25 | $1.1B | $1.5B | ||
| Q1 25 | $1.1B | $1.5B | ||
| Q4 24 | $999.2M | $1.5B | ||
| Q3 24 | $928.1M | $1.5B | ||
| Q2 24 | $858.4M | $1.5B |
负债/权益比HRMYROG
| Q1 26 | — | — | ||
| Q4 25 | 0.19× | — | ||
| Q3 25 | 0.20× | — | ||
| Q2 25 | 0.22× | — | ||
| Q1 25 | 0.24× | — | ||
| Q4 24 | 0.27× | — | ||
| Q3 24 | 0.31× | — | ||
| Q2 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $126.2M | $5.8M |
| 自由现金流经营现金流 - 资本支出 | $126.0M | $1.1M |
| 自由现金流率自由现金流/营收 | 51.7% | 0.5% |
| 资本支出强度资本支出/营收 | 0.0% | 2.3% |
| 现金转化率经营现金流/净利润 | 5.61× | 1.29× |
| 过去12个月自由现金流最近4个季度 | $347.9M | $70.1M |
8季度趋势，按日历期对齐
经营现金流HRMYROG
| Q1 26 | — | $5.8M | ||
| Q4 25 | $126.2M | $46.9M | ||
| Q3 25 | $108.7M | $28.9M | ||
| Q2 25 | $79.3M | $13.7M | ||
| Q1 25 | $34.0M | $11.7M | ||
| Q4 24 | $75.6M | $33.7M | ||
| Q3 24 | $70.5M | $42.4M | ||
| Q2 24 | $42.6M | $22.9M |
自由现金流HRMYROG
| Q1 26 | — | $1.1M | ||
| Q4 25 | $126.0M | $42.2M | ||
| Q3 25 | $108.7M | $21.2M | ||
| Q2 25 | $79.3M | $5.6M | ||
| Q1 25 | $33.9M | $2.1M | ||
| Q4 24 | $75.0M | $18.3M | ||
| Q3 24 | $70.5M | $25.2M | ||
| Q2 24 | $42.0M | $8.8M |
自由现金流率HRMYROG
| Q1 26 | — | 0.5% | ||
| Q4 25 | 51.7% | 20.9% | ||
| Q3 25 | 45.4% | 9.8% | ||
| Q2 25 | 39.6% | 2.8% | ||
| Q1 25 | 18.3% | 1.1% | ||
| Q4 24 | 37.3% | 9.5% | ||
| Q3 24 | 37.9% | 12.0% | ||
| Q2 24 | 24.3% | 4.1% |
资本支出强度HRMYROG
| Q1 26 | — | 2.3% | ||
| Q4 25 | 0.0% | 2.3% | ||
| Q3 25 | 0.0% | 3.6% | ||
| Q2 25 | 0.0% | 4.0% | ||
| Q1 25 | 0.1% | 5.0% | ||
| Q4 24 | 0.3% | 8.0% | ||
| Q3 24 | 0.0% | 8.2% | ||
| Q2 24 | 0.4% | 6.6% |
现金转化率HRMYROG
| Q1 26 | — | 1.29× | ||
| Q4 25 | 5.61× | 10.20× | ||
| Q3 25 | 2.14× | 3.36× | ||
| Q2 25 | 1.99× | — | ||
| Q1 25 | 0.75× | — | ||
| Q4 24 | 1.53× | — | ||
| Q3 24 | 1.53× | 3.96× | ||
| Q2 24 | 3.68× | 2.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
